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Abstract
Purpose: To assess the immediate efficacy of distinct embolisation devices in the endovascular treatment of pulmonary 
arteriovenous malformations as well as to identify and analyse the possible determinants of the technical success of 
the procedure.
Material and methods: Prospective analysis of 16 consecutive patients was carried out, who underwent transcatheter 
endovascular embolisation therapy for pulmonary arteriovenous malformations between 2005 and 2017. Pre- and 
post-procedural angiography studies were implemented to confirm the diagnosis and to evaluate the technical suc-
cess defined as the complete occlusion of the feeding artery. Embolisation devices – coils, microcoils, occluders, or 
combination of the above – were used. All the patients were advised to conduct a follow-up computed tomography 
evaluation 12 months after the procedure.
Results: A total of 40 pulmonary arteriovenous malformations (PAVMs) were observed and embolised. The im-
mediate technical success was achieved in all (n = 40; 100%) treated PAVMs, as confirmed by the post-procedural 
angiographic result. The statistical analysis revealed no significant impact of the number of PAVMs per patient  
(p > 0.05), their angioarchitecture (p > 0.05), localisation within the lung (p > 0.05) or particular lobe (p > 0.05), and 
the selection of embolisation device (p > 0.05) on the procedural success rates. The procedure-related complication 
rate was equal to 6.25%.
Conclusions: The immediate success rate of the transcatheter PAVM embolisation reached 100% in this study. The 
statistical model of logistic regression revealed no significant impact of the number of PAVMs per patient, their 
angioarchitecture, localisation, and distribution pattern, as well as device selection, on the immediate technical 
success of the procedure.
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Introduction
Pulmonary arteriovenous malformation (PAVM) is a rare 
clinical occurrence with a reported incidence rate of 1 in 
100,000 individuals. The estimated female-to-male ra-
tio ranges from 1.5 : 1 to 1.8 : 1. PAVM is a pathologic 
direct communication between the feeding pulmonary 
artery branch and the dysplastic, aneurysmal pulmo-
nary vein that results in right-to-left shunt. The shunt is 
predisposing for the development of paradoxical embo-
lisation – a major cause of PAVM-related mortality [1]. 
The malformations can be classified as simple (approxi-
mately 80%) with a unique feeding vessel and singular 
draining vein, or complex [1, 2]. A large majority of the 
pulmonary AVMs (50-83%) are multiple and located with-
in the inferior lobes [1, 2]. 
As much as 90% of the lesions are expected to be 
associated with the hereditary haemorrhagic telangiecta-
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sia (HHT), known as the Osler-Weber-Rendu syndrome, 
which is an autosomal dominant disease [1, 2]. This im-
plies careful screening for the disease in individuals with 
PAVMs, who have not been previously diagnosed with 
Osler-Weber-Rendu disease [1]. 
The condition may be clinically silent or manifest as 
either respiratory or neurological disorders [1, 2]. A high 
percentage of occult visceral malformations (PAVMs in 
53% cases) was detected in the study by Giordano et al. 
performed in a group of 35 paediatric patients with genet-
ically-confirmed diagnosis of HHT [3]. In addition, a ret-
rospective cohort study aiming to assess the prevalence 
of silent brain infarcts (SBI) among patients with HHT re-
vealed that the SBI rate was higher in HHT patients with 
PAVMs when compared to that of the general population 
and HHT patients without pulmonary malformations [4]. 
According to Pollak et al., approximately 59% of patients 
with PAVMs will experience dyspnoea or exercise intol-
erance, 3% hemothorax, 18% transient ischaemic attacks, 
33% ischaemic stroke, and 23% cerebral abscess [5]. In-
terestingly, as reported by Shovlin et al., incidence rates 
of the severe neurological complications are independent 
of both the magnitude of the right-to-left shunt and the di-
ameter of the largest feeding artery (FA; determinants of 
severity of PAVMs) [6]. Conversely, the diffuse, bilateral 
pattern of the disease seems to be associated with higher 
mortality rates [7]. 
Considering the above-mentioned risks associated 
with PAVMs, an attentive and meticulous diagnostic ap-
proach seems to be of the utmost importance. However, 
the task is particularly challenging, as the study results 
indicate that as much as 14 to 80% of individuals with 
PAVMs may be diagnosed accidentally, by incidental in-
vestigations or PAVM screening programmes in families 
with HHT [2, 6]. In addition, merely 20% of patients had 
PAVMs diagnosed by the imaging modalities or oxygen-
ation measurements performed due to respiratory symp-
toms [6]. It is therefore essential to distinguish individuals 
with high risk of PAVMs, i.e. those with clinical features 
suggestive of the disorder or with suspected or known 
diagnosis of the HHT, and initiate diagnostic evaluation 
in this group [8, 9]. Assessing the presence and magnitude 
of the right-to-left shunt by means of transthoracic con-
trast echocardiography (TTCE) is advised as the initial 
screening approach. Positive screening results should be 
confirmed with unenhanced chest computed tomography 
(CT) with thin-cut reconstructions [8]. Patients quali-
fied for embolotherapy based on prior CT evaluation are 
referred for a catheter pulmonary angiography, which 
remains the gold standard in the diagnosis of PAVM. 
The modality is applied with the primary purpose of di-
agnosis confirmation and therapeutic management [9]. In 
addition, it enables visualisation of the detailed angioar-
chitecture of even the smallest PAVMs, which contribute 
to device selection process.
Although no results of the randomised, controlled 
trial have been published yet, the collective observation-
al data suggest that transcatheter embolisation is an ef-
fective and safe procedure that contributes to decreased 
PAVM-associated morbidity and mortality rates [1, 6]. 
In addition, there is general agreement that the role of 
surgical interventions should be restricted to the man-
agement of emergency situations including haemorrhag-
es [1, 8]. Major indications for the embolotherapy com-
prise: the prevention of the life-threatening neurological 
(i.e. ischaemic stroke, cerebral abscess) and pulmonary 
haemorrhagic complications, as well as improvement in 
exercise tolerance [1, 6, 10]. Recent publications stress 
the importance of PAVM treatment in both symptomat-
ic and asymptomatic patients amenable to embolisation, 
even if the feeding artery diameter is less than 3 mm. In 
such cases, the procedure was proven to serve as protec-
tion against bacterial spread and paradoxical embolisation 
[1, 5, 8]. The primary procedure’s goal of PAVM emboli-
sation is the occlusion of the feeding vessel, which may be 
accompanied by the closure of the venous aneurysmal sac 
to achieve improved outcomes in complex malformations 
[1, 11, 12]. 
Because the complete eradication of PAVMs in peo-
ple with HHT is impossible due to the persistence of 
previously treated lesions and formation of new lesions, 
a long-term follow-up by means of CT of the thorax is 
highly recommended [1, 8]. As assessed during consec-
utive CT examinations, the permanent success is defined 
by the following criteria: disappearance or marked reduc-
tion (30-70% shrinkage) of the PAVM remnant and/or 
lack of enhancement of the AVP sac and adjacent draining 
vein in contrast-enhanced scans [13]. 
The authors aimed to assess the immediate efficacy of 
distinct embolisation devices in the endovascular treat-
ment of pulmonary arteriovenous malformations, as well 
as to identify and analyse the possible determinants of the 
technical success of the procedure. 
Material and methods
We performed a prospective analysis of 16 consecutive 
patients who underwent transcatheter endovascular em-
bolisation therapy for pulmonary arteriovenous malfor-
mations between 2005 and 2017. 
The inclusion criteria comprised the presence of 
PAVM confirmed by diagnostic imaging (including 
pre-procedural angiography) and either one of the fol-
lowing: presence of clinical symptoms (e.g. pulmonary 
haemorrhage, hypoxaemia), feeding artery diameter 
> 3 mm, or rapid enlargement of the lesion confirmed by 
imaging studies. The exclusion criteria included generally 
accepted contraindications to embolotherapy, i.e. severe 
chronic kidney disease without availability of dialysis and 
every pulmonary hypertension.
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Patient demographics (age, sex) and symptomatolog-
ical information were obtained from the hospital docu-
mentation. Diagnostic, procedural, and equipment details 
were obtained from the local radiological information 
system. 
Embolisation procedures were performed under local 
anaesthesia, using the Siemens Artis angiography sys-
tem setup. Each patient was administered with a 5000 IU 
bolus of heparin immediately prior to embolisation, to 
prevent clot formation and the risk of cerebral emboli-
sation. Pre- and post-procedural angiography studies 
were implemented to confirm the diagnosis and evalu-
ate technical success defined as the complete occlusion 
of the feeding artery with no evidence of residual blood 
flow through the PAVM, respectively. In each case, the 
transfemoral venous approach with 5-6 F, 65 cm-long 
vascular sheath was executed to reach the main pulmo-
nary artery, with subsequent selective embolisation of the 
PAVM feeding branch with a 5 F Vert or Cobra catheter. 
An additional coaxial 2.7 F micro-catheter (Progreat®, 
Terumo Interventional Systems) was used if applicable. 
The embolisation device (pushable 0.035” coil, 0.018” 
microcoil, Amplatzer™ occluder, or a combination of 
the above) was selected based on the size of the feeding 
vessel and angioarchitecture of the lesion, as visualised 
during pre-procedural angiography. 
All the patients were advised to conduct a follow-up 
CT evaluation 12 months after the procedure or upon 
symptom recurrence. 
The statistical analysis was performed using Statistica 
v. 12.0 (StatSoft Poland). Numerical data were presented 
as mean ± standard deviation and median values, whereas 
categorical data were given in absolute frequencies and 
percentages. Logistic regression was applied to investi-
gate the possible impact of the particular variables (num-
ber and localisation of PAVMs, embolisation device) on 
the immediate technical outcome of the procedure. A val-
ue of p < 0.05 indicated statistical significance. 
Results
There were 16 patients included in the study: 10 women 
and 6 men (female-to-male ratio 1.67 : 1) aged between 
22 and 77 years (mean age 44.63 ± 17.47 years, median 
= 40 years). One patient (n = 1; 6.25%) had a confirmed 
diagnosis of HHT. A total of 40 PAVMs were observed. 
In eight (50%) patients the lesions were multiple and lo-
calised bilaterally (Fig. 1), in seven (43.75%) patients they 
were single and unilateral (Fig. 2), and in one (6.25%) pa-
tient they were multiple and unilateral. A large majority 
of PAVMs (n = 31; 77.5%) occupied inferior lobes of the 
lungs. Only three (7.5%) PAVMs had complex angioar-
chitecture. Detailed angioarchitecture and distribution 
characteristics of the malformations are listed in Table 1. 
Fifteen out of 16 patients required a single-step proce-
dure. One patient (n = 1; 6.25%) required a two-stage 
procedure (Fig. 3) due to numerous PAVMs localised bi-
laterally. The technical success was assessed per stage in 
this case. The majority (n = 16; 40%) of PAVMs were em-
bolised using a combination of 0.038” pushable coils with 
0.018” microcoils, indicating the need for dense filling of 
the coil scaffold in order to achieve complete immediate 
technical success. In addition, only a single need to sup-
port the use of Amplatzer™ vascular plug with additional 
coil implantation shows the great potential of this device 
to serve as a solitary, effective measure of simple PAVM 
treatment. Treatment approach and device selection char-
acteristics are presented in Table 2.
The procedure-related complication rate was 6.25% 
(n = 1 patient). Blood-tinged sputum was observed in 
one patient during coil embolisation of a complex PAVM, 
which was probably caused by punctuation of one of the 
supplying arterial branches by the tip of the guide wire. 
The condition was self-limiting, and a complete resolu-
tion of symptoms was achieved within 15 minutes. Con-
trol erect chest radiograph and specialist consultation 
confirmed no pathology. 
Immediate technical success was achieved in all (n = 40; 
100%) treated PAVMs, as confirmed by the post-proce-
dural angiographic result. The statistical analysis revealed 
no significant impact of the number of PAVMs per patient 
(p > 0.05), their angioarchitecture (p > 0.05), localisation 
within the lung (p > 0.05) or particular lobe (p > 0.05), 
and the selection of embolisation device (p > 0.05) on the 
procedural success rates.
Discussion
The reported female-to-male ratio (1.67 : 1) of PAVM in-
cidence among the studied population is in accordance 
with previously published data [1]. The statistics concern-
ing distribution of the lesions within the lungs (77.5% 
PAVMs localised in the inferior lobes), their angioarchi-
tecture (92.5% of simple lesions), and multiplicity (56.25% 
patients with multiple PAVMs) are consistent with the 
literature [1, 2, 12]. However, the reported prevalence of 
HHT among the studied population (6.25%) is far from 
the generally accepted estimations [1, 2]. This indicates 
the further necessity for thorough genetic and clinical 
examination of patients who meet at least some of the 
Curaçao diagnostic criteria for HHT [1, 6]. Nonetheless, 
study results presented by Shovlin et al. do not support 
extensive screening in asymptomatic children [6].
The immediate technical success rate, defined as the 
occlusion of FA visible on angiogram obtained just after 
embolisation, which was adapted for the purpose of this 
study, reached 100% (n = 16). These results are also con-
sistent with the previously published data, which indicate 
the success rates between 80% and 100% regardless of 
the embolisation material [5, 10, 14-16]. The statistical 
analysis proved the results to be independent of the num-
ber of PAVMs embolised, their angioarchitecture, local-
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isation, and distribution pattern as well as device selec-
tion. These results are also consistent with the previously 
published data, which indicate success rates between 80% 
and 100% regardless of the embolisation material [5, 10, 
14-16]. 
The selection of the embolisation device is mostly 
determined by the angioarchitecture and feeding artery 
diameter of the lesion [1]. In general, PAVMs with FA 
diameter > 3 mm may be supplied with the Amplatzer™ 
vascular occluder (St. Jude Medical). The device allows 
for safe and convenient positioning and redeployment 
under fluoroscopic guidance, to achieve the best possi-
ble direct occlusion of the supplying vessel. The mech-
anism of action of the vascular plug can be compared 
to previously described detachable-balloons, which were 
withdrawn from the market. The reported effectiveness 
Figure 1. 25-year-old female patient with multiple bilateral pulmonary arteriovenous malformations 
(PAVMs) treated with Amplatzer™ vascular plug and coils. A) 3D angio-CT reconstruction showing 
the existence of bilateral malformations (thick arrows). B) Selective angiography visualises single 
feeding artery to the PAVM located within left lung. C) Post-embolisation control angiography depicts 
the effective occlusion of the distal feeding artery with the Amplatzer™ device. D) Contralateral 
fistulas of the right lung. E) Branching feeding artery of the medial fistula efficiently occluded with 
the Amplatzer™ plug (arrowhead). Supplying vessel to the lateral PAVM effectively supplied with 
coils. F-G) 12-month follow-up computed tomography scans depicting adequate localisation of the 
embolisation devices and successful occlusion of the PAVMs with no signs of residual blood flow
A B C
D
G
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of the procedures performed using the Amplatzer™ device 
are promising, with an estimated 100% immediate technical 
success rates and 0-7% reperfusion rates [1, 14, 15, 17]. 
Embolisation experience with 0.035” pushable coils has 
been broadly published. Unlike the vascular occluder, fi-
bre coverage of the coils evokes indirect vessel occlusion 
due to activation of the platelet aggregation [1, 5, 18]. 
It has been learned over time that dense packing of the 
coils is essential to achieve a durable result, especially 
because a large diameter of the FA has been associated 
with elevated risk for reperfusion [5, 14]. This in turn, 
may form a niche for the use of micro delivery equip-
ment along with platinum detachable microcoils. The 
combined use of both the 0.035” and 0.018” devices may 
lead to increased packing density and, therefore, contrib-
ute to reduced distant reperfusion rates. In addition, mi-
cro equipment may be employed during embolisation of 
distal pulmonary arterial branches that are not amenable 
Table 1. Detailed localisation and angioarchitecture of pulmonary arteriovenous malformations (PAVMs)
Lung Lobe Total n PAVMs n PAVMs Angioarchitecture
n simple n complex*
Right Superior 17 (42.5%) 3 3 n/a
Middle 2 2 n/a
Inferior 12 (30%) 10 2
Left Superior 23 (57.5%) 4 3 1
Inferior 19 (47.5%) 19 n/a
40 (100%) 37 (92.5%) 3 (7.5%)
*Complex angioarchitecture refers to PAVMs with feeding artery to draining vein ratio other than 1:1 
n – number of lesions; n/a – not applicable
A B C
D E
Figure 2. 42-year-old female patient with a unique aneurys-
mal pulmonary arteriovenous malformation (PAVM) located in 
the left lung. A) Axial computed tomography scan indicating 
the presence of PAVM (circle). B) Selective angiography of the 
left pulmonary artery confirms the diagnosis of PAVM. Feeding 
artery (arrowhead) and venous aneurysmal sac (thick arrow) 
are indicated. C) Super selective angiography of the feeding 
branch indicates the existence of a simple PAVM. The feeding 
artery (arrowheads) and venous aneurysmal sac (thick arrow) 
are indicated. D) Post-procedural selective angiography (ar-
terial phase) presenting coil deposition (red arrows) within 
the aneurysmal sac and the feeding branch. E) Late phase of 
the post-procedural angiography indicates no residual flow 
through the PAVM
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for catheterisation with standard 4-5 F guiding catheters, 
and thus constitute a promising treatment option for pa-
tients with diffuse pattern of small PAVMs. However, 
such observations have not been supported by White, 
who advocates that the use of microcoils adds to the cost 
and complexity of the embolisation procedure [11, 19]. 
Nonetheless, if one decides to perform a procedure with 
the use of the microcoils, caution should be applied to 
avoid non-target embolisation, particularly in high-flow 
malformations [12].
Figure 3. 36-year-old female patient diagnosed with hereditary haemorrhagic telangiectasia (HHT) and multiple bilateral pulmonary arteriovenous mal-
formations (PAVMs). A) 3D angio-CT reconstruction shows the existence of numerous lesions in both lungs (red circles). B) First stage of the procedure. 
Multiple PAVMs localised in the lower lobe of the left lung. C) Pre-embolisation angiography of a high-flow simple malformation. Coils visible inside the 
occluded feeding arteries of the already treated malformations (arrowheads). D-E) Second stage of embolisation. Successful occlusion of the lesions of the 
right lung. F) Control angiography performed after second stage of embolisation indicates effective occlusion of all treated PAVMs
A
F
B C
D E
Table 2. Device/treatment selection with respect to pulmonary arteriovenous malformation angioarchitecture
Pushable 0.038” 
coils
0.018” 
microcoils
0.038” pushable coils + 
0.018” microcoils
Amplatzer™ 
occluder
Amplatzer™ occluder 
0.038” + pushable coils
n simple 8 6 15 7 1 37
n complex n/a 1 1 n/a 1 3
Total n PAVMs 8 7 16 7 2 40
n – number of lesions, n/a – not applicable
It should be stressed, however, that the encouraging 
initial results do not translate into long-term efficacy of the 
embolisation procedure [14]. Persistence of the PAVM is 
defined as continued perfusion through the lesion after its 
endovascular treatment and may occur in either of the two 
mechanisms: recanalisation or reperfusion. Recanalisation 
is associated with reestablishment of the flow through the 
previously occluded feeding artery, and it accounts for as 
much as 90% of persistent PAVMs. Conversely, reperfu-
sion develops as a result of the pulmonary-to-pulmonary or 
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systemic-to-pulmonary connections [5, 14, 16]. According 
to the literature, there is a substantial difference in PAVM 
persistence between embolisation with use of coils and 
embolisation with use of vascular plugs [14, 16]. Report-
ed experience with the Amplatzer™ occluder has shown 
low reperfusion rates of 0-7%, perhaps with even better 
results when the plug was combined with the use of coils 
[13]. Persistence rates after initial treatment with the use 
of coils alone were as high as 8-25% [14, 16]. Nonethe-
less, no randomised controlled trials have been executed 
until present to compare the efficacy of selected types of 
embolisation coils. The authors of this publication express 
their hope that a current clinical trial, aimed to compare 
reperfusion rates observed after the use of Nester coil and 
Interlock Fibered IDC Occlusion System, will elucidate 
this matter to some extent [20].
A recent study by Martin et al. indicates that both 
primary and recurrent recanalisation rates are influenced 
also by the post-embolisation antithrombotic therapy 
(OR = 15.21, 95% CI: 1.54-150.13, p = 0.020 and 
OR = 6.40, 95% CI: 1.31-31.26, p = 0.02, respectively). 
These observations pose a new challenge for the clini-
cians to consider when prescribing antithrombotic agents 
to patients with HHT [21]. 
The observed complication rates in our cohort were 
equal to 6.25% (n = 1). The self-limiting haemoptysis oc-
curred during the procedure and was probably caused by 
punctuation of a small arterial branch with the tip of the 
guide wire. This implies that embolisation is a safe and 
effective procedure for pulmonary arteriovenous malfor-
mations.
There were certain limitations to this study. Firstly, the 
study population (n = 16) was small, which might have 
influenced the outcome of the analysis. Secondly, it was 
impossible to conduct a multivariate statistical analysis 
to assess the possible relationship between the immediate 
technical success and the diameter of the feeding artery 
and selected equipment, due to incomplete hospital docu-
mentation concerning the exact type and size of the cho-
sen devices. In addition, despite the fact that the patients 
were advised to undergo a follow-up CT scan 12 months 
after the embolisation, the scans could have not be includ-
ed in the analysis of long-term results of the procedures 
due to the following issues: (i) CT evaluation scans of 
11 (68.75%) subjects are still pending because the em-
bolisation was performed in less than 12 months; (ii) fol-
low-up CT scans (n = 3) performed in regional centres 
differ in terms of slice thickness; and (iii) some patients 
(n = 2) were lost to follow-up. 
Based on the above observations, the authors of this 
publication are convinced that individuals with HHT 
should be referred to a specialised centre, where exten-
sive, targeted care may be executed. It is also of the ut-
most importance to introduce definite follow-up criteria 
that would include exact CT scan parameters to enable 
reliable comparative studies regarding the long-term effi-
cacy of the particular embolisation devices. 
Conclusions
The immediate success rate of the transcatheter PAVM 
embolisation reached 100% in this study, regardless of 
the device selection. The statistical model of logistic re-
gression revealed no significant impact of the number of 
PAVMs per patient, their angioarchitecture, localisation, 
and distribution pattern as well as device selection on the 
immediate technical success of the procedure.
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